| Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen |
| Biotech Stocks At 52-Week Highs - Cumberland Pharmaceuticals, Maravai LifeSciences, AngioDynamics, Acadia Healthcare, Teladoc Health | BENTONVILLE (dpa-AFX) - The following biotech stocks reached a 52-week high on July 15, 2026, driven by catalysts such as recent business developments or positive quarterly reports.Cumberland... ► Artikel lesen |
| Teladoc Health, Inc.: Teladoc Health Reports First Quarter 2026 Results | NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2026 ("First... ► Artikel lesen |
| Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen |
| Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen |
| Sernova Biotherapeutics: Sernova Biotherapeutics Announces Closing of Recently Approved Financings | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading... ► Artikel lesen |
| Cerenome, Inc.: Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment | Capital will support continued CNSide commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028... ► Artikel lesen |
| Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update | HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics... ► Artikel lesen |
| Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective... ► Artikel lesen |